{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-035162","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2022-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.788391+00:00","generated_at":"2026-06-21T06:13:21.785526+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"AgeX stockholders approve doubling authorized shares to 200M and adding 4M shares to equity plan","bullets":["Elected directors Bailey, Hackett, May, West with ~20.4M-20.7M votes each; 5.2M broker non-votes.","Ratified WithumSmith+Brown as auditor for FY2022: 26.8M for, 31K against.","Approved amendment to increase authorized common stock from 100M to 200M shares (20.8M for, 1.3M against).","Approved 2017 Equity Incentive Plan amendment adding 4M shares, total now 8.5M shares available (20.1M for).","Approved Juvenescence proposal to acquire >19.9% or 50%+ of AGE shares via warrants/loan conversion (20.4M for)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-035162","json":"https://secwatch.observer/filing/0001493152-22-035162.json","markdown":"https://secwatch.observer/filing/0001493152-22-035162.md","text":"https://secwatch.observer/filing/0001493152-22-035162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000149315222035162/0001493152-22-035162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000149315222035162/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T06:13:21.785526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07a5556e8437318d809e8448981feb5df5dbcb8a","claim":"Serina Therapeutics, Inc. shareholders approved Common Stock Amendment Proposal - amendment to Certificate of Incorporation to increase authorized shares from 100,000,000 to 200,000,000 at the 2022-12-07 meeting.","evidence_excerpt":"Common Stock Amendment Proposal The Common Stock Amendment Proposal was approved by the following vote: Shares Voted For 20,798,910 Against 1,341,037 Abstain 22,781 In addition, there were 4,736,638 broker non-votes on this matter.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315222035162/0001493152-22-035162-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-07"}],"fact_type":"shareholder_vote"},{"claim_id":"3120e897fb4fa48a08f00a1e1ffde61174fc79bc","claim":"Serina Therapeutics, Inc. shareholders approved Incentive Plan Amendment Proposal - amendment of 2017 Equity Incentive Plan to make additional 4,000,000 shares available at the 2022-12-07 meeting.","evidence_excerpt":"Incentive Plan Amendment Proposal The Incentive Plan Amendment Proposal was approved by the following vote: Shares Voted For 20,127,120 Against 1,474,349 Abstain 53,488 In addition, there were 5,244,408 broker non-votes on this matter.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315222035162/0001493152-22-035162-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-07"}],"fact_type":"shareholder_vote"},{"claim_id":"4696cb2e1cb2c6c096cea10de84237664580c817","claim":"Serina Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accountants at the 2022-12-07 meeting.","evidence_excerpt":"Ratification of Appointment of Independent Registered Public Accountants The appointment of WithumSmith + Brown PC as our independent registered public accountants for the fiscal year ending December 31, 2022 was ratified by the following vote: Shares Voted For 26,776,985 Against 31,458 Abstain 90,923 There were no broker non-votes on this matter.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315222035162/0001493152-22-035162-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-07"}],"fact_type":"shareholder_vote"},{"claim_id":"c3da56e6408f19e3dadd1ead39da5eebad3a219c","claim":"Serina Therapeutics, Inc. shareholders approved Election of Directors at the 2022-12-07 meeting.","evidence_excerpt":"Election of Directors Each of the following nominees were elected as directors by the following vote: Nominee Votes For Votes Withheld Gregory Bailey 20,443,999 1,210,959 Joanne Hackett 20,457,478 1,197,480 Michael May 20,469,901 1,185,057 Michael D. West 20,685,723 969,235 In addition, there were 5,244,408 broker non-votes with respect to the election of directors.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315222035162/0001493152-22-035162-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-07"}],"fact_type":"shareholder_vote"},{"claim_id":"e18dcee5065bd23cbf447eba0b6b882d1856125d","claim":"Serina Therapeutics, Inc. shareholders approved Juvenescence Proposal - to permit Juvenescence Limited to acquire additional shares of AgeX common stock through exercise of warrants or conversion of loans at the 2022-12-07 meeting.","evidence_excerpt":"Juvenescence Proposal The Juvenescence was approved by the following vote: Shares Voted For 20,393,670 Against 1,204,612 Abstain 56,676 In addition, there were 5,244,408 broker non-votes on this matter.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315222035162/0001493152-22-035162-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-07"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}